Salicylazosulfapyridine: Target Organs and Levels of Evidence for TR-457
Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CASRN 599-79-1) in F344 Rats and B6C3F1 Mice (Gavage Studies)
Chemical (Study Title) CASRN |
Peer Review Date |
Route/Exposure Levels |
Study Laboratory |
Salicylazosulfapyridine 599-79-1 |
|
Gavage R: 0, 84, 169, OR 337 M: 0, 675, 1350, OR 2700 MG/KG |
T.S.I. Mason Laboratories, Inc. |
Levels of Evidence: None
Chemical (Study Title) CASRN |
Peer Review Date |
Route/Exposure Levels |
Study Laboratory |
Salicylazosulfapyridine 599-79-1 |
06/20/1995 |
Gavage R: 84, 168, OR 337.5 MG/KG; 70/GROUP M: 675, 1350, OR 2700 MG/KG; 60/GROUP |
Southern Research Institute |
Levels of Evidence
Male Rats: Some Evidence
Type |
Organ/Tissue (Lesion) |
Neoplastic Lesions |
- Urinary Bladder: (CORE STUDY) TRANSITIONAL CELL PAPILLOMA 0/50 0/49 2/50 6/50
|
Non-Neoplastic Lesions |
- URINARY BLADDER: (CORE STUDY) CONCRETION; DILATATION; (CORE AND STOP STUDY) TRANSITIONAL CELL HYPERPLASIA
- KIDNEY: (CORE STUDY) CONCRETION; HYDRONEPHROSIS; (CORE AND STOP STUDY) TRANSITIONAL CELL HYPERPLASIA; MINERALIZATION; RENAL TUBULE DILATATION
- SPLEEN: (CORE AND STOP STUDY) HEMOSIDEROSIS; HEMATOPOIETIC CELL PROLIFERATION
|
Other Considerations |
- VARIOUS ORGANS: MONONUCLEAR CELL LEUKEMIA 13/50 18/50 12/50 3/50
|
Female Rats: Some Evidence
Type |
Organ/Tissue (Lesion) |
Neoplastic Lesions |
- Kidney Transitional Cell: PAPILLOMA 0/50 0/50 0/50 2/50
- Urinary Bladder: TRANSITIONAL CELL PAPILLOMA 0/49 0/50 2/50 0/50
|
Non-Neoplastic Lesions |
- URINARY BLADDER: HYPERPLASIA
- KIDNEY: CONCRETION; TRANSITIONAL CELL HYPERPLASIA; HYDRONEPHROSIS; NEPHROPATHY
|
Other Considerations |
- VARIOUS ORGANS: MONONUCLEAR CELL LEUKEMIA 14/50 9/50 8/50 3/50
|
Male Mice: Clear Evidence
Type |
Organ/Tissue (Lesion) |
Neoplastic Lesions |
- Liver: ADENOMA 13/50 32/50 28/50 42/50 OR CARCINOMA 13/50 15/50 23/50 8/50 COMBINED 24/50 38/50 38/50 44/50
|
Non-Neoplastic Lesions |
- LIVER: EOSINOPHILIC FOCI
- SPLEEN: HEMATOPOIETIC CELL PROLIFERATION; HEMOSIDEROSIS
|
Other Considerations |
- FORESTOMACH: HYPERPLASIA 18/50 11/50 11/49 10/50
|
Female Mice: Clear Evidence
Type |
Organ/Tissue (Lesion) |
Neoplastic Lesions |
- Liver: ADENOMA 12/50 28/50 25/50 28/49 OR CARCINOMA 2/50 10/50 10/50 9/49 COMBINED 14/50 32/50 28/50 29/49
|
Non-Neoplastic Lesions |
- LIVER: EOSINOPHILIC FOCI
- SPLEEN: HEMATOPOIETIC CELL PROLIFERATION; HEMOSIDEROSIS
|
Other Considerations |
- FORESTOMACH: SQUAMOUS CELL PAPILLOMA 5/50 1/50 1/50 0/50; HYPERPLASIA 12/50 6/49 4/50 4/49
|
Chemical (Study Title) CASRN |
Peer Review Date |
Route/Exposure Levels |
Study Laboratory |
Salicylazosulfapyridine 599-79-1 |
06/20/1995 |
Gavage |
Southern Research Institute |
Levels of Evidence
Male Rats: Some Evidence
Type |
Organ/Tissue (Lesion) |
Neoplastic Lesions |
- Urinary Bladder: (CORE STUDY) TRANSITIONAL CELL PAPILLOMA 0/50 0/49 2/50 6/50
|
Non-Neoplastic Lesions |
- URINARY BLADDER: (CORE STUDY) CONCRETION; DILATATION; (CORE AND STOP STUDY) TRANSITIONAL CELL HYPERPLASIA
- KIDNEY: (CORE STUDY) CONCRETION; HYDRONEPHROSIS; (CORE AND STOP STUDY) TRANSITIONAL CELL HYPERPLASIA; MINERALIZATION; RENAL TUBULE DILATATION
- SPLEEN: (CORE AND STOP STUDY) HEMOSIDEROSIS; HEMATOPOIETIC CELL PROLIFERATION
|
Other Considerations |
- VARIOUS ORGANS: MONONUCLEAR CELL LEUKEMIA 13/50 18/50 12/50 3/50
|
Female Rats: Some Evidence
Type |
Organ/Tissue (Lesion) |
Neoplastic Lesions |
- Kidney Transitional Cell: PAPILLOMA 0/50 0/50 0/50 2/50
- Urinary Bladder: TRANSITIONAL CELL PAPILLOMA 0/49 0/50 2/50 0/50
|
Non-Neoplastic Lesions |
- URINARY BLADDER: HYPERPLASIA
- KIDNEY: CONCRETION; TRANSITIONAL CELL HYPERPLASIA; HYDRONEPHROSIS; NEPHROPATHY
|
Other Considerations |
- VARIOUS ORGANS: MONONUCLEAR CELL LEUKEMIA 14/50 9/50 8/50 3/50
|
Male Mice: Clear Evidence
Type |
Organ/Tissue (Lesion) |
Neoplastic Lesions |
- Liver: ADENOMA 13/50 32/50 28/50 42/50 OR CARCINOMA 13/50 15/50 23/50 8/50 COMBINED 24/50 38/50 38/50 44/50
|
Non-Neoplastic Lesions |
- LIVER: EOSINOPHILIC FOCI
- SPLEEN: HEMATOPOIETIC CELL PROLIFERATION; HEMOSIDEROSIS
|
Other Considerations |
- FORESTOMACH: HYPERPLASIA 18/50 11/50 11/49 10/50
|
Female Mice: Clear Evidence
Type |
Organ/Tissue (Lesion) |
Neoplastic Lesions |
- Liver: ADENOMA 12/50 28/50 25/50 28/49 OR CARCINOMA 2/50 10/50 10/50 9/49 COMBINED 14/50 32/50 28/50 29/49
|
Non-Neoplastic Lesions |
- LIVER: EOSINOPHILIC FOCI
- SPLEEN: HEMATOPOIETIC CELL PROLIFERATION; HEMOSIDEROSIS
|
Other Considerations |
- FORESTOMACH: SQUAMOUS CELL PAPILLOMA 5/50 1/50 1/50 0/50; HYPERPLASIA 12/50 6/49 4/50 4/49
|